Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world

• DOI: 10.1016/j.dib.2018.04.092
• Publication Date: 2018-05-01T05:19:48Z
• Authors: Anselm K. Gitt; Dominik Lautsch; Jean Ferrières; Gaetano M. De Fer...; Ami Vyas; Carl A. Baxter; Lori D. Bash; Veronica Ashton; Martin Horack; Wael Almahmeed; Fu-Tien Chiang; Kian Keong Poh; Philippe Brudi; Baishali Ambegaonkar
• Keywords: Science (General); 330; Computer applications to medicine. Medical informatics; Statins; R858-859.7; 610; Global; 3. Good health; Q1-390; 03 medical and health sciences; 0302 clinical medicine; Medicine and Dentistry; Low-density lipoprotein cholesterol; Region; Treatment target

DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean low-density lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects.While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value.